ICCC - ImmuCell Corporation

Momentum: Bearish

Recent News

ImmuCell Swings to Q2 Profit on Strong Sales, Shares Still Slide

Zacks Commentary • 3 weeks, 4 days ago • score: 0.32

ICCC posts Q2 profit on higher sales and margins, but shares fall as investors weigh one-time boosts and Re-Tain's delayed commercialization.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.

52W High

$7.60

52W Low

$3.34

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.30

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

30.14

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

13.22

EV/Revenue (<3 favorable)

2.32

P/S (TTM) (<3 favorable)

2.03

P/B (<3 favorable)

1.92

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

27.89%

Institutions (25–75% balanced)

20.10%

Shares Outstanding

9,045,800

Float

6,016,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

28,274,800

Gross Profit (TTM)

10,994,100

EPS (TTM)

0.21

Profit Margin (>10% good)

0.06%

Operating Margin (TTM) (higher better)

0.09%

ROE (TTM) (>15% strong)

0.07%

EPS YoY (Quarterly) (>10% good)

-0.63

Revenue YoY (Quarterly) (>8% good)

0.18

Momentum

Bearish momentum

Value

-0.0676

-0.0333

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025